Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 30, 2020
Daily News
September 30, 2020
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Independent Monitoring Panel Kicks Off Discussions; MHLW-PMDA Collaboration, Ad Rules among Topics
September 30, 2020
- EFPIA Global, Japan Chiefs Call for Appropriate Reward for Innovation
September 30, 2020
- Fetroja Approved for Nosocomial Pneumonia in US
September 30, 2020
- Kentaro Enomoto to Take Over Councilor Post for Health Insurance on October 1: MHLW
September 30, 2020
- Fujifilm Kyowa Kirin’s Avastin Biosimilar Approved in Europe
September 30, 2020
- Torii Enjoys Stellar Performance from Corectim, 1st JAK Med for Atopic Dermatitis
September 30, 2020
- MHLW Urges Healthcare Stakeholders to Comply with Distribution Guidelines Even in COVID-19 Outbreak
September 30, 2020
- Alnylam Seeks Japan Approval of RNAi Drug Givosiran for Acute Hepatic Porphyrias
September 30, 2020
- JCR Files Sakigake-Designated Pabinafusp Alfa for Hunter Syndrome
September 30, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…